Pfizer's Bococizumab cuts "bad" cholesterol in mid-stage study

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer's (PFE) Bococizumab (RN316) met the primary goal of a Phase IIb trial, significantly lowering LDL-C cholesterol across several dosing regimens in patients with a high risk of cardiovascular events.

Bococizumab is part of a set of treatments known as PCSK9 inhibitors, which several major pharmaceuticals companies are working on. (PR)